Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 12;1(5):e00219-16.
doi: 10.1128/mSphere.00219-16. eCollection 2016 Sep-Oct.

Development of a Nanobody-Based Lateral Flow Immunoassay for Detection of Human Norovirus

Affiliations

Development of a Nanobody-Based Lateral Flow Immunoassay for Detection of Human Norovirus

Sylvie Y Doerflinger et al. mSphere. .

Abstract

Human noroviruses are the dominant cause of outbreaks of acute gastroenteritis. These viruses are usually detected by molecular methods, including reverse transcriptase PCR (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). Human noroviruses are genetically and antigenically diverse, with two main genogroups that are further subdivided into over 40 different genotypes. During the past decade, genogroup 2 genotype 4 (GII.4) has dominated in most countries, but recently, viruses belonging to GII.17 have increased in prevalence in a number of countries. A number of commercially available ELISAs and lateral flow immunoassays were found to have lower sensitivities to the GII.17 viruses, indicating that the antibodies used in these methods may not have a high level of cross-reactivity. In this study, we developed a rapid Nanobody-based lateral flow immunoassay (Nano-immunochromatography [Nano-IC]) for the detection of human norovirus in clinical specimens. The Nano-IC assay detected virions from two GII.4 norovirus clusters, which included the current dominant strain and a novel variant strain. The Nano-IC method had a sensitivity of 80% and specificity of 86% for outbreak specimens. Norovirus virus-like particles (VLPs) representing four genotypes (GII.4, GII.10, GII.12, and GII.17) could be detected by this method, demonstrating the potential in clinical screening. However, further modifications to the Nano-IC method are needed in order to improve this sensitivity, which may be achieved by the addition of other broadly reactive Nanobodies to the system. IMPORTANCE We previously identified a Nanobody (termed Nano-85) that bound to a highly conserved region on the norovirus capsid. In this study, the Nanobody was biotinylated and gold conjugated for a lateral flow immunoassay (termed Nano-IC). We showed that the Nano-IC assay was capable of detecting at least four antigenically distinct GII genotypes, including the newly emerging GII.17. In the clinical setting, the Nano-IC assay had sensitivities equivalent to other commercially available lateral flow systems. The Nano-IC method was capable of producing results in ~5 min, which makes this method useful in settings that require rapid diagnosis, such as cruise ship outbreaks and elder care facilities. The Nano-IC assay has several advantages over antibody-based IC methods: for example, Nanobodies can be readily produced in large quantities, they are generally more stable than conventional antibodies, and the Nanobody binding sites can be easily obtained by X-ray crystallography.

Keywords: Nanobody; lateral flow assay; norovirus.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Analysis of Nano-85 binding to clinical norovirus specimens and VLPs. (A) Representative lateral flow strip assay showing the positive signal for norovirus detection. (B) Sensitivities and specificities of the Nano-IC, Nano-ELISA, and Ridascreen methods. (C) Phylogenetic analysis of the 17 isolated capsid sequences (amino acid) from the outbreak (numbered XX-14) and sporadic infections (numbered XX-15). The Nano-IC results are represented as follows: *, positive reading; neg, negative reading; and nt, not tested. Representative genotypes are also included in the phylogenetic analysis. The bootstrap values are shown on the branches.
FIG 2
FIG 2
Sequence and structural analysis of the Nano-85 binding site. (A) Amino acid sequence alignment (partial shown) of two representative clinical specimens and other GII genotypes. The binding site of the Nano-85 is indicated (shaded orange) (9). (B) The GII.10 protruding domain (gray) and Nano-85 (orange) (4X7E). The GII.10 protruding domain residues interacting with Nano-85 are shown in green. (C) GII.1 (4ROX), GII.12 (3R6K), and GII.17 (5F4O) protruding domains (gray) were superpositioned on the GII.10 P domain Nano-85 complex. The protruding domain residues that likely interacted with Nano-85 are shown (GII.1, lemon; GII.10, green; GII.12, pale green; and GII.17, forest), and Pro464GII.1 was colored in cyan.

References

    1. Ozawa K, Oka T, Takeda N, Hansman GS. 2007. Norovirus infections in symptomatic and asymptomatic food handlers in Japan. J Clin Microbiol 45:3996–4005. doi:10.1128/JCM.01516-07. - DOI - PMC - PubMed
    1. Kroneman A, Vega E, Vennema H, Vinjé J, White PA, Hansman G, Green K, Martella V, Katayama K, Koopmans M. 2013. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 158:2059–2068. doi:10.1007/s00705-013-1708-5. - DOI - PMC - PubMed
    1. Hansman GS, Natori K, Shirato-Horikoshi H, Ogawa S, Oka T, Katayama K, Tanaka T, Miyoshi T, Sakae K, Kobayashi S, Shinohara M, Uchida K, Sakurai N, Shinozaki K, Okada M, Seto Y, Kamata K, Nagata N, Tanaka K, Miyamura T, Takeda N. 2006. Genetic and antigenic diversity among noroviruses. J Gen Virol 87:909–919. doi:10.1099/vir.0.81532-0. - DOI - PubMed
    1. Siebenga JJ, Vennema H, Renckens B, de Bruin E, van der Veer B, Siezen RJ, Koopmans M. 2007. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol 81:9932–9941. doi:10.1128/JVI.00674-07. - DOI - PMC - PubMed
    1. Nenonen NP, Hannoun C, Svensson L, Torén K, Andersson LM, Westin J, Bergström T. 2014. Norovirus GII.4 detection in environmental samples from patient rooms during nosocomial outbreaks. J Clin Microbiol 52:2352–2358. doi:10.1128/JCM.00266-14. - DOI - PMC - PubMed

LinkOut - more resources